Part 3 of 4: Practical Steps in Organizing your Clinic for Long-Acting IM Therapy

HIV 24/7 | Practical Considerations for Long-Acting Antiretroviral Therapy

Part 4 of 4: Tips to Minimize Injection Site Reactions

HIV 24/7 | Practical Considerations for Long-Acting Antiretroviral Therapy

Part 2 of 4: Key Topics to Discuss with Your Patient before Starting Long-Acting Therapy

HIV 24/7 | Practical Considerations for Long-Acting Antiretroviral Therapy

Part 1 of 4: Checklist for Clinician for Optimal Initiation of Long Acting IM Therapy

HIV 24/7 | Practical Considerations for Long-Acting Antiretroviral Therapy

HIV 24/7 | Practical Considerations for Long-Acting Antiretroviral Therapy

19th INTEREST 2025

First Speaker Against the Proposition - Everline Ashiono, MMed, MBChB

INTEREST 2024

First Speaker Against the Proposition - Everline Ashiono, MMed, MBChB

INTEREST 2024

Eliminating HIV in Children - Why is Africa Behind? - Ivy Kasirye, MBChB, MMed, MSc

INTEREST 2024

Eliminating HIV in Children - Why is Africa Behind? - Ivy Kasirye, MBChB, MMed, MSc

INTEREST 2024

HPV and HIV Elimination of a double burden_Sabrina Kitaka_INTEREST_2024.pdf

INTEREST 2024

Differentiated HIV Care for Adolescents living with HIV_INTEREST 2024_Sabrina Kitaka_FINAL FINAL.pdf

INTEREST 2024

Update on Long Acting ART for PrEP and Treatment - François Venter, MD, FCP, PhD

INTEREST 2024

Kidney Impairment in HIV: An Insight Into the Burden and Associated Factors Among Adults on Antiretroviral Therapy (ART) in Zambia - Matenge Mutalange, Zambia

INTEREST 2024

Prevalence and Associated Factors of Chronic Kidney Disease in Young People Living With HIV in Uganda - Esther Nasuuna, Uganda

INTEREST 2024

C-Reactive Protein (CRP) and HIV Are Independent Predictors of Cognitive Performance Among Children and Adults From Kampala, Uganda - Lois Bayigga, Uganda

INTEREST 2024

Silent Struggles Unveiled: High Prevalence of Depression, Suicidal Behavior, and Substance Abuse Among Adolescents and Young Adults Living With HIV Select Facilities in Malawi - Louiser Upile Kalitera, Malawi

INTEREST 2024

Distribution et Determinants du Risque D’Evenements Cardiovasculaires Chez Les Personnes Vivant Avec Le Virus de L’Immuno-Deficience Humaine a L’Hopital Central de Yaounde - Liliane Mfeukeu, Cameroon

INTEREST 2024

Access to Innovative Biomedical Treatment and Prevention Tools in Low- and Middle-Income Countries - Tiwadayo Braimoh, MSc, MBA

INTEREST 2024

North and South Research Partnership - Glenda E. Gray, MBBCH, FCPaeds (SA), DSc

INTEREST 2024

ANRS MIE - Inmaculada Ortega Perez, PhD, MPH

INTEREST 2024

Plasma Viral Load of 200 Copies/ML Is a Suitable Threshold to Define Viral Suppression and HIV Drug Resistance Testing in Low- And Middle- Income Countries: Evidence From a Facility-Based Study in Cameroon - Collinis Ambe Chenwi, Cameroon

INTEREST 2024

Effect of the COVID-19 Pandemic on Paediatric Antiretroviral Therapy Coverage in Sub–Saharan Africa: Findings From 43 Countries - Stella Atema, Nigeria

INTEREST 2024

Transitioning Children to Pediatric Dolutegravir (TORPEDO) Study: Endline Results in Benin, Nigeria, and Uganda - Dinesh Rathakrishnan, United States

INTEREST 2024